Indaptus Therapeutics, Inc. (INDP) Form 424B3 — Aug 26, 2026
Indaptus Therapeutics filed a prospectus registering the resale of up to 58,895,000 shares of common stock, approximately 44.2% of its 133,242,324 shares outstanding, by selling stockholders. The company receives no proceeds from these sales; the block consists of 20,000,000 shares from a June 2026 private placement and 38,895,000 shares from the conversion of Series AAA preferred stock traced to the December 2025 David Lazar investment.
Key figures
- Shares Offered
- 58895000
- Shares Outstanding
- 133242324
- Authorized common shares
- 1000000000
- June 2025 reverse split ratio
- 1-for-28
- December 2025 lazar investment
- $6,000,000 at $6.00 per preferred share
- Last reported close aug 25 2026
- 1.1
- June 2026 private placement shares
- 20000000
- March 2026 share sale purchase price
- $11,200,000
- Lazar residual ownership post transfer
- approximately 1.82%
- Purchaser group ownership post transfer
- approximately 96.2%
- Percent of shares outstanding registered
- 44.2%
- June 2026 private placement gross proceeds
- $12,000,000
- June 2026 private placement price per share
- 0.6
- Shares from series aaa preferred conversion
- 38895000
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.